It is estimated that around 250 people will be eligible to have Namuscla
It is estimated that around 250 people will be eligible to have Namuscla
Dunad will apply its own platform to generate the novel covalent and targeted protein degrading small molecule drugs
Back in 2019, esketamine was commercialised as Spravato, described as a “breakthrough” medication used to treat depression
Bamlanivimab and etesevimab are intended for use in COVID patients at high risk of disease progression
Indonesia becomes the first country to authorise the vaccine
Belgium leads in country rankings by the value of exports this year, followed by Germany and the US
93% of clinicians felt that remote medicine was worse than in-person consultations in terms of accuracy
AstraZeneca has announced it will transfer global rights to respiratory meds Eklira and Duaklir to Covis Pharma
HRT treats menopause symptoms by replacing hormones that are at a lower level for those experiencing it
Anyone who received their second dose at least six months ago can now receive their booster at one of these sites
The companies will evaluate Trodelvy plus Keytruda for the first-line treatment of certain triple-negative breast cancer patients
GammaDelta is focused on research into gamma delta T cells for potential use in immunotherapy, primarily addressing solid tumours
Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor for the alternative pathway of the complement system
The winners of the 2021 Clinical Researcher of the Year – The Americas have been announced, find out who emerged victorious
Experts say that it is vital to ensure that every member who is eligible for a vaccine has received one